Elicio Therapeutics, Inc. (ELTX)
NASDAQ: ELTX · Real-Time Price · USD
8.54
+0.44 (5.43%)
At close: Feb 21, 2025, 4:00 PM
8.96
+0.42 (4.92%)
After-hours: Feb 21, 2025, 6:54 PM EST
Elicio Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
32
Market Cap
92.03M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ELTX News
- 22 days ago - Elicio: Lymph Node Binding With ELI-002 Could Lead To Substantial 1st Half 2025 Data - Seeking Alpha
- 4 weeks ago - Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy - GlobeNewsWire
- 2 months ago - Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024 - GlobeNewsWire
- 3 months ago - Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 3 months ago - Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting - GlobeNewsWire
- 4 months ago - Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit - GlobeNewsWire
- 4 months ago - Elicio Therapeutics Reports Inducement Grants - GlobeNewsWire
- 5 months ago - Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines - GlobeNewsWire